Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB2 | P05107 | 8/20 | 0.47 |
| ▸ | ICAM1 | P05362 | 8/20 | 0.47 |
| ▸ | ITGAL | P20701 | 8/20 | 0.47 |
| ▸ | FPR2 | P25090 | 1/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.45 |
| ▸ | ACE | P12821 | 3/20 | 0.44 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.44 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.44 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.44 |
| ▸ | ECE1 | P42892 | 3/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31158208 | 0.84 | ITGB2 (0.56) | ITGB2ICAM1ITGALFPR2ALOX15 | |
| SCHEMBL30955895 | 0.80 | ADAM17 (0.55) | ITGB2ICAM1ITGALALOX15ACE | |
| SCHEMBL12885480 | 0.80 | NPSR1 (0.66) | ALOX15 | |
| SCHEMBL18523423 | 0.80 | NPSR1 (0.66) | ALOX15 | |
| SCHEMBL31575704 | 0.80 | NPSR1 (0.66) | ALOX15 | |
| SCHEMBL29478383 | 0.79 | ITGB2 (0.56) | ITGB2ICAM1ITGALALOX15ACE | |
| SCHEMBL14532940 | 0.79 | HTR7 (0.56) | ITGB2ICAM1ITGALALOX15ACE | |
| SCHEMBL29984984 | 0.79 | HTR2A (0.58) | ITGB2ICAM1ITGALALOX15MTNR1A | |
| SCHEMBL30138755 | 0.79 | TSHR (0.59) | ITGB2ICAM1ITGALMTNR1AMTNR1B | |
| SCHEMBL26693248 | 0.79 | KMT2A (0.64) | ALOX15CSNK2A1MTNR1AMTNR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8268856-B2 | Method to use compositions having antidepressant anxiolytic and other neurological activity and compositions of matter | HAMANN MARK T (US) | 2012-09-18 | — | — | US | disclosed |
| US-20120029010-A1 | METHOD TO USE COMPOSITIONS HAVING ANTIDEPRESSANT ANXIOLYTIC AND OTHER NEUROLOGICAL ACTIVITY AND COMPOSITIONS OF MATTER | HAMANN MARK T (US) | 2012-02-02 | — | — | US | disclosed |
| EP-2209380-A1 | METHOD TO USE COMPOSITIONS HAVING ANTIDEPRESSANT ANXIOLYTIC AND OTHER NEUROLOGICAL ACTIVITY AND COMPOSITIONS OF MATTER | Triton Biopharma, Llc (US) | 2010-07-28 | — | — | EP | disclosed |
| WO-2009049030-A1 | METHOD TO USE COMPOSITIONS HAVING ANTIDEPRESSANT ANXIOLYTIC AND OTHER NEUROLOGICAL ACTIVITY AND COMPOSITIONS OF MATTER | TRITON BIOPHARMA, LLC (US) | 2009-04-16 | — | — | WO | disclosed |
| US-20090093513-A1 | Method to Use Compositions Having Antidepressant Anxiolytic and Other Neurological Activity and Compositions of Matter | HAMANN, MARK T. | 2009-04-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120029010-A1 | METHOD TO USE COMPOSITIONS HAVING ANTIDEPRESSANT ANXIOLYTIC AND OTHER NEUROLOGICAL ACTIVITY AND COMPOSITIONS OF MATTER | ACHE, CHAT, HTR3D | ITGB2 2376/4885ICAM1 3636/4885ITGAL 2203/4885 |
| US-20090093513-A1 | Method to Use Compositions Having Antidepressant Anxiolytic and Other Neurological Activity and Compositions of Matter | ACHE, CHAT, HTR3D | ITGB2 2376/4885ICAM1 3636/4885ITGAL 2203/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.